Dublin, Feb. 21, 2019 (GLOBE NEWSWIRE) -- The "Viral Vector & Plasmid DNA Manufacturing Market Analysis Report By Application, By Disease (Cancer, Genetic), By Workflow (Upstream, Downstream), By Vector, By End Use, And Segment Forecasts, 2019 - 2025" report has been added to ResearchAndMarkets.com's offering.
The global viral vector & plasmid DNA manufacturing market size is expected to reach USD 882.9 million by 2025, rising at a 16.0% CAGR during the forecast period.
Rising number of gene therapy-based discovery programs in the pharma industry is one of the key trends driving the production of gene therapy vectors. Moreover, a robust pipeline of viral vaccines and gene therapies has prompted companies to develop novel and effective technologies for scalable manufacturing of vectors. Current vector manufacturing process is considered highly regulated, elaborate, and expensive.
Moreover, at present, there is a shortage of production sites to meet the demand by the pharmaceutical industry for vector construction services. These factors have created opportunities for companies to capitalize on potential avenues in the market through developing novel solutions.
Key growth strategies adopted by companies to sustain their market presence include continuous expansion of manufacturing sites in high-demand markets such as the U.S. and U.K. Moreover, companies are engaged in strategic mergers & facility acquisitions to meet growing requirements of viral vectors within the pharmaceutical and biotech industries and to broaden their service portfolios.
Further Key Findings From the Report Suggest:
- Adenovirus and retrovirus were prominent vector type segments in the market in 2017. These can be produced at high titers and induce a strong humoral and, especially, a strong T cell response, as a result of which these vector type is extensively employed in vaccines
- Lentiviral production costs nearly up to 40.0% of the total cost of goods, thus inducing revenue growth in this vector type
- Downstream processing accounted for the largest share in 2017, owing to requirement of expensive equipment and skilled personnel for product recovery
- In terms of application, vector manufacturing for antisense, RNAi, & molecular therapy production represented the leading revenue share in 2017. This is due to high adoption rate of viruses for oligonucleotide and aptamers development in comparison to other applications
- The number of biotech companies that are engaged in employing vector for therapeutic production continue to increase over the period
- Recent approval of cancer gene therapy products encourages further efforts in this arena, thus resulting in the cancer segment holding the dominant revenue share
- North America led the global market owing to presence of several universities and research institutes that are engaged in genomic research programs
- Cobra Biologics, Merck, uniQure N.V., and Novasep are some key participants that are focusing towards capitalizing of untapped avenues in the market.
Key Topics Covered:
Chapter 1 Executive Summary
1.1 Market Snapshot
Chapter 2 Research Methodology
2.1 Information Procurement
2.2 Data Analysis
2.3 Market Formulation & Validation
2.4 Approaches for Market Estimation
Chapter 3 Viral Vector & Plasmid DNA Manufacturing Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Robust pipeline for gene therapies and viral vector vaccines
3.1.1.2 Technological advancements for vector production
3.1.1.3 Highly competitive market and various marketing strategies undertaken by the operating entities
3.1.2 Market restraint analysis
3.1.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy
3.1.3 Challenge analysis
3.1.3.1 Production capacity challenges
3.1.3.2 Manufacturing challenges pertaining to the production of vector at large scale
3.1.4 Opportunity analysis
3.1.4.1 Facility expansion for cell and gene therapies
3.1.4.2 Investments, collaboration & partnerships in cell and gene therapies space
3.2 Penetration & Growth Prospect Mapping For Vector Type, 2017
3.3 Viral Vector & Plasmid DNA Manufacturing Market-Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.4 Industry Analysis - Porter's
Chapter 4 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Vector Type Estimates & Trend Analysis
4.1 Viral Vector & Plasmid DNA Manufacturing Market: Vector Type Movement Analysis
4.2 Adenovirus
4.3 Retrovirus
4.4 Plasmid DNA
4.5 AAV
4.6 Lentivirus
4.7 Other Vectors
Chapter 5 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Workflow Estimates & Trend Analysis
5.1 Viral Vector & Plasmid DNA Manufacturing Market: Workflow Movement Analysis
5.2 Upstream Manufacturing
5.2.2 Vector amplification & expansion
5.2.3 Vector recovery/harvesting
5.3 Downstream Manufacturing
5.3.2 Purification
5.3.3 Fill-finish
Chapter 6 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Application Estimates & Trend Analysis
6.1 Viral Vector & Plasmid DNA Manufacturing Market: Application Movement Analysis
6.2 Antisense, RNAi, & Molecular Therapy
6.3 Vaccinology
Chapter 7 Viral Vector & Plasmid DNA Manufacturing Market Categorization: End-use Estimates & Trend Analysis
7.1 Viral Vector & Plasmid DNA Manufacturing Market: End-use Movement Analysis
7.2 Pharmaceutical and Biopharmaceutical Companies
7.3 Research Institutes
Chapter 8 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Disease Estimates & Trend Analysis
8.1 Viral Vector & Plasmid DNA Manufacturing Market: Disease Movement Analysis
8.2 Cancer
8.3 Genetic disorders
8.4 Infectious diseases
8.5 Others
Chapter 9 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Regional Estimates & Trend Analysis
9.1 Viral Vector & Plasmid DNA Manufacturing Market Share By Regional, 2017 & 2025
9.2 North America
9.3 Europe
9.4 Asia Pacific
9.5 Latin America
9.6 MEA
Chapter 10 Competitive Landscape
10.1 List of Companies With Portfolio for Vector-based Therapeutic Candidate
10.2 List of Vector Manufacturers
10.3 Strategy Framework
10.4 Market Participation Categorization
10.5 Company Profiles
- Merck KGaA
- Lonza
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
- Cobra Biologics Ltd.
- Brammer Bio
- Waisman Biomanufacturing
- Genezen
- Yposkesi
- Regenxbio, Inc.
- Cell and Gene Therapy Catapult
For more information about this report visit https://www.researchandmarkets.com/research/9rdhnj/global_882_9_mn?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.